Lifevantage (LFVN) to Release Quarterly Earnings on Thursday

Key Points

• Lifevantage is expected to report Q4 2026 earnings after the market closes on Thursday, August 27, with analysts forecasting $0.15 in earnings per share and $44 million in revenue.
• LFVN shares recently traded at $6.50, up 2%, with a market capitalization of approximately $82 million; the stock has ranged from $3.90 to $14.28 over the past year.
• Analysts maintain a consensus “Hold” rating with an average price target of $5.00, while institutional investors and hedge funds own 35.32% of the company.

Lifevantage (NASDAQ:LFVN - Get Free Report) is expected to post its Q4 2026 results after the market closes on Thursday, August 27th. Analysts expect the company to post earnings of $0.15 per share and revenue of $44.00 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Thursday, August 27, 2026 at 4:30 PM ET.

Lifevantage Trading Up 2.0%

NASDAQ LFVN opened at $6.50 on Thursday. The stock has a fifty day simple moving average of $6.49 and a 200-day simple moving average of $5.77. The stock has a market cap of $82.00 million, a PE ratio of 14.44 and a beta of 0.72. Lifevantage has a twelve month low of $3.90 and a twelve month high of $14.28.

Analyst Ratings Changes

LFVN has been the subject of several research analyst reports. Weiss Ratings raised shares of Lifevantage from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, May 26th. Lake Street Capital downgraded shares of Lifevantage from a "buy" rating to a "hold" rating and set a $5.00 price target on the stock. in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $5.00.

Institutional Investors Weigh In On Lifevantage

Institutional investors have recently modified their holdings of the company. Osaic Holdings Inc. lifted its stake in Lifevantage by 780.3% during the 2nd quarter. Osaic Holdings Inc. now owns 14,270 shares of the company's stock worth $187,000 after acquiring an additional 12,649 shares in the last quarter. Invesco Ltd. boosted its holdings in Lifevantage by 13.6% during the 4th quarter. Invesco Ltd. now owns 30,085 shares of the company's stock valued at $185,000 after acquiring an additional 3,603 shares during the period. Cetera Investment Advisers grew its position in Lifevantage by 29.4% in the 4th quarter. Cetera Investment Advisers now owns 25,405 shares of the company's stock valued at $156,000 after acquiring an additional 5,771 shares in the last quarter. Virtu Financial LLC acquired a new position in Lifevantage in the 4th quarter valued at about $146,000. Finally, Price T Rowe Associates Inc. MD increased its stake in Lifevantage by 33.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,234 shares of the company's stock worth $113,000 after purchasing an additional 4,600 shares during the period. 35.32% of the stock is owned by institutional investors and hedge funds.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company's flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source